Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderich E Schwarz

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
The Journal of Surgical Research|December 4, 2012
Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancerChanghua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
The Journal of Surgical Research|June 15, 2007
Androgen receptor blockade in experimental combination therapy of pancreatic cancerSrivani Konduri, Margaret A Schwarz, Danielle Cafasso, et al.
Journal of Cellular and Molecular Medicine|September 3, 2024
Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma modelsNiranjan Awasthi, Lily Darman, Margaret A Schwarz, et al.
International Journal of Oncology|September 18, 2013
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancerChang-Ηua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
Journal of Cellular Biochemistry|October 25, 2011
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancerNiranjan Awasthi, Peter L Yen, Margaret A Schwarz, et al.
Cancer Letters|November 26, 2002
Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatmentRoderich E Schwarz, Cecile A Donohue, David Sadava, et al.
The Journal of Surgical Research|December 19, 2023
Surgeon-Dependent Variability in Cost of Gastrointestinal Operations in a Single Cancer CenterJoy Sarkar, Richard P Roehner, Michael J Proulx, et al.
The American Journal of Case Reports|April 3, 2018
Managing the Unmanageable: A Two-Staged Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent ParagangliomaLevi Y Smucker, Ashley N Hardy, Peter J O'Neil, et al.
Annals of Surgical Oncology|December 31, 2009
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancerRoderich E Schwarz, Niranjan Awasthi, Srivani Konduri, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 19, 2013
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP IINiranjan Awasthi, Changhua Zhang, Stefan Hinz, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
The Journal of Surgical Research|December 4, 2012
Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancerChanghua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
The Journal of Surgical Research|June 15, 2007
Androgen receptor blockade in experimental combination therapy of pancreatic cancerSrivani Konduri, Margaret A Schwarz, Danielle Cafasso, et al.
Journal of Cellular and Molecular Medicine|September 3, 2024
Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma modelsNiranjan Awasthi, Lily Darman, Margaret A Schwarz, et al.
International Journal of Oncology|September 18, 2013
The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancerChang-Ηua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
Journal of Cellular Biochemistry|October 25, 2011
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancerNiranjan Awasthi, Peter L Yen, Margaret A Schwarz, et al.
Cancer Letters|November 26, 2002
Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatmentRoderich E Schwarz, Cecile A Donohue, David Sadava, et al.
The Journal of Surgical Research|December 19, 2023
Surgeon-Dependent Variability in Cost of Gastrointestinal Operations in a Single Cancer CenterJoy Sarkar, Richard P Roehner, Michael J Proulx, et al.
The American Journal of Case Reports|April 3, 2018
Managing the Unmanageable: A Two-Staged Palliative Resection to Control Life-Threatening Duodenal Bleeding Due to Recurrent ParagangliomaLevi Y Smucker, Ashley N Hardy, Peter J O'Neil, et al.
Annals of Surgical Oncology|December 31, 2009
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancerRoderich E Schwarz, Niranjan Awasthi, Srivani Konduri, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 19, 2013
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP IINiranjan Awasthi, Changhua Zhang, Stefan Hinz, et al.
Pageof 11